Despite an increasing number of clinical trials confirming the superiority of FXR agonists in treating NAFLD, the quantity of FXR agonists entering clinical research is limited, and many exhibit noticeable side effects. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.